MENLO PARK, Calif. (AP) _ Intersect ENT Inc. (XENT) on Tuesday reported a loss of $4.8 million in its fourth quarter.
The Menlo Park, California-based company said it had a loss of 17 cents per share.
The results beat Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.
The maker of absorbable nasal implants posted revenue of $24.2 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $23.7 million.
For the year, the company reported that its loss narrowed to $25.2 million, or 89 cents per share. Revenue was reported as $78.7 million.
For the current quarter ending in April, Intersect ENT said it expects revenue in the range of $19 million to $19.5 million.
The company expects full-year revenue in the range of $87 million to $89 million.
Intersect ENT shares have risen 12 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $13.60, a drop of 25 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XENT at https://www.zacks.com/ap/XENT
Keywords: Intersect ENT, Earnings Report